Transgenomic Announces Medicare Coverage for Clopidogrel (Plavix®) Response Test
08:00 EDT 24 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Transgenomic, Inc. (OTCBB: TBIO) today announced that National
Government Services, the designated Medicare fiscal intermediary in
Connecticut, has confirmed coverage for its proprietary Clopidogrel
Genetic Absorption Activation...
Other Sources for this Article
Investor Contact
Argot Partners
David Pitts,
212-600-1902
david@argotpartners.com
or
Company
Contact
Transgenomic, Inc.
Investor Relations
402-452-5416
investorrelations@transgenomic.com
More From BioPortfolio on "Transgenomic Announces Medicare Coverage for Clopidogrel (Plavix®) Response Test"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
